Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Rating of “Hold” by Brokerages

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has received an average recommendation of “Hold” from the twelve research firms that are currently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $109.70.

ITCI has been the subject of several research analyst reports. Wall Street Zen initiated coverage on shares of Intra-Cellular Therapies in a research report on Thursday, May 15th. They issued a “hold” rating for the company. Mizuho downgraded shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $132.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Intra-Cellular Therapies by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock valued at $811,928,000 after acquiring an additional 93,107 shares in the last quarter. Pentwater Capital Management LP acquired a new stake in Intra-Cellular Therapies during the first quarter valued at approximately $684,665,000. Norges Bank acquired a new stake in Intra-Cellular Therapies during the fourth quarter valued at approximately $268,347,000. Invesco Ltd. lifted its position in shares of Intra-Cellular Therapies by 2.9% in the 4th quarter. Invesco Ltd. now owns 3,077,174 shares of the biopharmaceutical company’s stock valued at $257,006,000 after acquiring an additional 87,582 shares in the last quarter. Finally, Deep Track Capital LP lifted its position in shares of Intra-Cellular Therapies by 24.9% in the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $167,040,000 after acquiring an additional 399,307 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Price Performance

ITCI opened at $131.87 on Friday. The firm has a market capitalization of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. The firm’s 50 day moving average is $131.87 and its 200-day moving average is $119.71. Intra-Cellular Therapies has a 52-week low of $66.26 and a 52-week high of $131.98.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.